The specific release of the drug from the conjugates in the tumour environment was ensured by inserting cathepsin B cleavable spacers, namely either the tetrapeptide GFLG or LRRY, between the homing peptide and the drug [48,49]. This evidence concerns the gene CTSB and neoplasm.